Prevalence and Characteristics of Patients With Metastatic Cancer Who Receive No Anticancer Therapy
|
|
- Allan Fisher
- 5 years ago
- Views:
Transcription
1 Prevalence and Characteristics of Patients With Metastatic Cancer Who Receive No Anticancer Therapy Alexander C. Small, BA 1 ; Che-Kai Tsao, MD 1 ; Erin L. Moshier, MS 2 ; Benjamin A. Gartrell, MD 1 ; Juan P. Wisnivesky, MD, DrPH 3,4 ; James H. Godbold, PhD 2 ; Cardinale B. Smith, MD 1 ; Guru Sonpavde, MD 5,6 ; William K. Oh, MD 1 ; and Matthew D. Galsky, MD 1 BACKGROUND: A subset of patients who present with metastatic solid tumors never receive anticancer therapy. Reasons may include poor functional status, comorbidities, and patient preference. To the authors knowledge, the prevalence and characteristics of this population have not previously been described. METHODS: The National Cancer Data Base was queried for patients diagnosed with metastatic (stage IV according to the American Joint Committee on Cancer) solid tumors (including those of the breast, cervix, colon, and kidney; small cell and nonsmall cell lung cancer [NSCLC]; and tumors of the prostate, rectum, and uterus) who received neither radiotherapy nor systemic therapy. Log-binomial regression analysis was used to estimate prevalence ratios (PRs) for the percentage of untreated to treated patients with stage IV cancer. RESULTS: Between 2000 and 2008, 773,233 patients with stage IV cancer were identified, 159,284 of whom (20.6%; 95% confidence interval, 20.5%-20.7%) received no anticancer therapy. Patients with NSCLC accounted for 55% of the untreated population. Patients with cancers of the kidney and lung had the highest rates of no treatment at 25.5% and 24.0%, respectively, whereas patients with prostate cancer had the lowest rate of no treatment at 11.1%. Across all cancer types, older age (PR range, ; all P <.001), black race (PR range, ; all P <.001), lack of medical insurance (PR range, ; all P <.001), and lower income (except for cancer of the uterus; PR range, for every $10,000- increase in income [all P <.001]) were associated with a lack of treatment. CONCLUSIONS: Approximately 20% of patients who present with stage IV solid tumors do not receive anticancer therapy. Although there are likely multiple reasons for this lack of treatment, including appropriate indications, these findings have potential implications with regard to health care policy and access to care. Cancer 2012;118: VC 2012 American Cancer Society. KEYWORDS: metastatic cancer, health care disparities, National Cancer Data Base, untreated, no treatment. INTRODUCTION Clinicians caring for patients with cancer are well aware that a subset of patients who present with metastatic solid tumors never receive anticancer therapy. Although advanced solid tumors are generally not curable with current therapeutic modalities, the use of systemic chemotherapy and radiotherapy has been associated with improvements in cancer-related symptoms, and prolongation of life, across multiple tumor types. 1,2 Despite these benefits, treatment may be forgone for several reasons including comorbidities, poor functional status, lack of access to care, and personal preference. 3,4 To the best of our knowledge, there has been scant literature describing the prevalence and characteristics of patients presenting with advanced cancer who receive no anticancer therapy. In 1 such study of 6308 patients diagnosed with stage IV nonsmall cell lung cancer (NSCLC) between 1991 and 1993, only 21.5% of patients received systemic therapy. 5 However, since the early 1990s, additional data have been generated to support the use of chemotherapy for advanced cancer and more tolerable treatment regimens have been developed. 6 A recent analysis of patients with urothelial cancer reported that 23.8% of patients with metastatic disease received no systemic therapy. 7 Studies of large populations of patients with cancer, across various tumor types, have to our knowledge not been performed previously to estimate the magnitude of potential undertreatment. Therefore, we sought to analyze the treatment patterns of patients presenting with metastatic cancer across 9 common cancer types using a contemporary cohort from a national cancer registry database. Corresponding author: Matthew D. Galsky, MD, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl, New York, NY 10029; Fax: (212) ; matthew.galsky@mssm.edu 1 Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York; 2 Department of Preventive Medicine, Mount Sinai School of Medicine, New York, New York; 3 Division of General Internal Medicine, Mount Sinai School of Medicine, New York, New York; 4 Division of Pulmonary and Critical Care Medicine, Mount Sinai School of Medicine, New York, New York; 5 Medical Oncology, Texas Oncology-Deke Slayton Cancer Center, Houston, Texas; 6 Section of Medical Oncology, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas DOI: /cncr.27658, Received: March 13, 2012; Revised: April 18, 2012; Accepted: April 20, 2012, Published online June 15, 2012 in Wiley Online Library (wileyonlinelibrary.com) Cancer December 1,
2 MATERIALS AND METHODS Data Source Data for this study were obtained from the National Cancer Database (NCDB) Public Benchmark Reports ( cromwell.facs.org/bmarks/bmpub/ver10/bm_reports. cfm) from 2000 through The NCDB is a national, hospital-based cancer registry jointly sponsored by the American College of Surgeons and the American Cancer Society. Since 1996, the Commission on Cancer (CoC) has required CoC-accredited programs to report cancers diagnosed or treated at their facilities to the NCDB. As of 2001, data collection has been restricted only to CoC-accredited programs, including > 1400 academic centers, cancer centers, community hospitals, and Veterans Affairs (VA) hospitals. The NCDB contains standardized data elements regarding patient demographics, tumor characteristics, and the first course of treatment. In addition, the NCDB contains information concerning patient insurance status, geographic location of residence, type of treatment facility, and income level. The NCDB Public Benchmark Reports provide access to aggregatelevel data categorized by multiple variables. 8 Previous studies have shown concordance between the NCDB data set and other national population and cancer registries for ethnicity distribution, age distribution, insurance status, and stage at diagnosis. 9 Because no patient, provider, or hospital identifiers are included in the research data set and no protected health information is present, Institutional Review Board approval was not required for this study. Patient Population Study participants were diagnosed with American Joint Committee on Cancer stage IV lung (NSCLC or small cell lung cancer [SCLC]), breast, kidney, prostate, colon, rectum, cervical, or uterine cancer and did not receive any first-course therapy. These cancers represent 5 of the most common solid tumors diagnosed in men and women in the United States. 10 The label no first-course therapy was selected to designate patients who refused any type of intervention, who died before the initiation of treatment, or for whom the treating physician recommended no treatment be given. Importantly, the no first-course therapy designation is actively selected by the cancer registrar and excludes patients with other or unknown first-course therapies. Patient Demographics and Socioeconomic Indicators Factors potentially associated with a lack of treatment were classified into 4 categories: clinical characteristics, patient-level demographics, area socioeconomic indicators, and facility characteristics. Data regarding stage of disease, year of diagnosis, and first-course therapy were extracted. Age at diagnosis was classified as a categorical variable using the following age groups: aged < 20 years to 49 years, aged 50 years to 59 years, aged 60 years to 69 years, aged 70 years to 79 years, aged 80 years to 89 years, and aged > 90 years. Race was defined by Facility Oncology Registry Data Standards (FORDS) criteria and categorized as white, black, Asian/Pacific Islander (API), and other/unknown. In terms of ethnicity, patients were classified as Hispanic or non-hispanic. Primary payer/insurance type at the time of diagnosis was also defined by FORDS criteria and was grouped into the following categories: private insurance plans (health maintenance organization, preferred provider organization, managed care, or private insurance), Medicaid, Medicare (Medicare alone or Medicare with supplement), uninsured (not insured, insurance not otherwise specified, charity writeoff, and self-pay), and military (VA or military/ TRICARE). Area-based indicators of patient socioeconomic status, specifically education and income, were derived by the NCDB from US census data at the ZIP code level, and divided into 5 equally proportional categories based on the observed distribution. The percentages of the population in the patient s ZIP code of residence without a high school degree were coded into the following groups: > 29%, 20% to 28.9%, 14% to 19.9%, and < 14%. The median household income for the patients ZIP code of residence was stratified into the following groups: < $28,000, $28,000 to $32,999, $33,000 to $38,999, $39,000 to $48,999, and > $49,000. Statistical Analyses The primary objective of the current study was to define the percentage of patients with stage IV cancer who received no anticancer therapy. An additional objective was to examine patient characteristics associated with a lack of treatment. Log-binomial regression analysis was used to estimate prevalence ratios (PRs) and corresponding 95% confidence limits (95% CL) relating the percentages of patients receiving no firstcourse therapy versus any therapy for stage IV cancer among categories of various socioeconomic and demographic variables. Statistical significance was defined as P <.05. All statistical analyses were performed using SAS statistical software (Version 9.2; SAS Institute Inc, Cary, NC) Cancer December 1, 2012
3 Untreated Metastatic Cancer/Small et al RESULTS Study Population Between 2000 and 2008, a total of 5,395,382 patients with breast, cervical, colon, and kidney cancer; NSCLC; SCLC; and prostate, rectal, and uterine cancer were identified in the NCDB. A total of 4,173,128 patients with stage 0 to III disease or an unknown disease stage were excluded (Fig. 1). Overall, 773,233 patients with stage IV cancers remained for the analysis. The distribution of stage IV cancers by primary tumor site is shown in Table 1 and illustrated by Figure 2. The distribution by stage at presentation, categorized by primary tumor site, is shown in Figure 3. The median age of patients with stage IV cancer was 60 years to 69 years. The lowest median age group was for patients with cervical cancer (aged 50 years-59 years) and the highest median age group was for patients with kidney cancer (aged 70 years-79 years). Overall, 32.6% of the patients with stage IV disease had private insurance (252,176 patients), 50.3% had Medicare (388,834 patients), 6.0% had Medicaid (46,260 patients), and 4.4% were uninsured (33,715 patients). The percentage of uninsured patients in the NCDB study population was greatest for cancers of the cervix (12.1%) and breast (5.8%) and was lowest for kidney (3.8%), colon (3.9%), and prostate (3.9%) cancer. The majority (621,197 patients; 80.3%) of patients with stage IV cancer were white. Overall, 12.5% (96,763 patients) of patients were black, 3.7% (28,713 patients) were Hispanic, and 1.9% (14,720 patients) were API. Figure 1. Flow chart detailing patients included in and excluded from analysis is shown. NSCLC indicates nonsmall cell lung cancer; SCLC, small cell lung cancer. Figure 2. Cancer-specific percentage of the total number of untreated patients with stage IV tumors is shown. NSCLC indicates nonsmall cell lung cancer; SCLC, small cell lung cancer. Table 1. Percentage of Patients With AJCC Stage IV Cancer Receiving No Anticancer Therapy Patients Kidney Uterus NSCLC SCLC Rectum Colon Prostate Breast Cervix Total Untreated patients 12, ,400 21, , ,284 with stage IV, no. Total with stage IV, no. 47, ,748 99,206 26, ,748 59,074 57, ,233 Percentage untreated 25.5% 24.4% 24.7% 21.3% 16.5% 15.7% 11.1% 12.8% 14.8% 20.6% 95% CL 25.1%- 25.9% 22.0%- 26.9% 24.6%- 24.9% 21.0%- 21.5% 16.0%- 16.9% 15.5%- 15.9% 10.9%- 11.4% 12.5%- 13.1% 14.1%- 15.5% 20.5%- 20.7% Abbreviations: 95% CL, 95% confidence limit; AJCC, American Joint Committee on Cancer; NSCLC, nonsmall cell lung cancer; SCLC, small cell lung cancer. Cancer December 1,
4 Figure 3. Cancer stage at the time of diagnosis in the National Cancer Data Base is shown. NSCLC indicates nonsmall cell lung cancer; SCLC, small cell lung cancer. Percentage of Untreated Patients Of the 773,233 patients with stage IV cancers, 159,284 (20.6%) received no anticancer therapy. The percentage of patients with stage IV tumors receiving no anticancer therapy, categorized by the site of the primary tumor, is detailed in Table 1. Patients with lung cancer accounted for 68% (108,485 patients) of the total of untreated patients with stage IV tumors. Patients with cancers of the colon (18,816 patients; 11.8%), kidney (12,079 patients; 7.6%,), breast (7313 patients; 4.6%), prostate (6582 patients; 4.1%), and rectum (4305 patients; 2.7%) accounted for the remaining majority of untreated patients (Fig. 2). Kidney cancer, NSCLC, and uterine cancer had the highest rates of no treatment at 25.5% (95% CL, 25.1%, 25.9%), 24.7% (95% CL, 24.6%, 24.9%), and 24.7% (95% CL, 22.0%, 26.9%), respectively, whereas prostate and breast cancer had the lowest rates at 11.1% (95% CL, 10.9%, 11.4%) and 12.8% (95% CL, 12.5%, 13.1%), respectively. Patient Characteristics and Association With Lack of Treatment Tables 2 and 3 present the distribution by patient age, gender, race/ethnicity, insurance status, and socioeconomic status of the untreated population with stage IV disease categorized by primary tumor site. Among the untreated patients, the majority (33.1%) were aged 70 years to 79 years. Overall, 20.8% of the untreated patients with stage IV disease had private insurance (33,108 patients), 61.6% had Medicare (98,138 patients), 5.3% had Medicaid (8403 patients), and 4.8% were uninsured (7639 patients). Among the untreated patients with stage IV disease, 79.5 % were white (126,676 patients), 13.1% were black (20,790 patients), 4.0% were Hispanic (6326 patients), and 1.8% were API (2853 patients). There were significant differences in the percentage of untreated stage IV cancers across gender, age, and racial categories (Fig. 4). Females had a higher likelihood of being untreated compared with men for kidney cancer (28.2% vs 24.0%; PR, 1.18 [P <.001]), SCLC (21.6% vs 21.0%; PR, 1.03 [P ¼.035]), rectal cancer (18.5% vs 15.2%; PR, 1.22 [P <.001]), and colon cancer (16.1% vs 15.3%; PR, 1.06 [P <.001]). Older patients were more likely to be untreated than younger patients across all cancer types. For every 10-year increase in age, the percentage of untreated patients increased by 35% (NSCLC: PR, 1.35; 95% CL, 1.34, 1.36 [P <.001]) to 49% (colon: PR, 1.49; 95% CL, 1.47, 1.51 [P <.001]). Blacks were significantly more likely to be untreated for stage IV cancer than whites for all tumors except uterine cancer and SCLC (PR range, ; all P <.001). Likewise, among patients with kidney cancer, NSCLC, SCLC, and prostate cancer, Hispanics were significantly more likely to be untreated than whites (PR range, ; all P <.001). Across all cancer types, patients 5950 Cancer December 1, 2012
5 Untreated Metastatic Cancer/Small et al Table 2. Percentage of Patients With Untreated AJCC Stage IV Cancer by Tumor Site and Demographic Characteristics (No. and Percentage Untreated) Characteristic Kidney Uterus NSCLC SCLC Rectum Colon Prostate Breast Cervix Total Gender Male ,283 11, , % 24.8% 21.0% 15.2% 15.3% 11.1% 20.7% Female , , % 24.4% 24.6% 21.6% 18.5% 16.1% 12.8% 14.8% 20.1% Age, y < % 9.9% 14.1% 11.4% 7.6% 6.4% 5.2% 6.5% 8.4% 10.3% , , % 14.2% 16.9% 13.5% 10.0% 8.5% 6.1% 9.3% 12.8% 13.4% , , % 20.6% 20.8% 17.3% 13.8% 12.0% 8.3% 11.7% 15.9% 17.4% , , % 23.8% 28.4% 25.4% 20.0% 17.2% 12.1% 16.0% 24.0% 24.4% , , % 43.8% 41.8% 40.1% 33.6% 28.3% 17.2% 24.5% 31.2% 35.1% > % 67.6% 61.6% 60.0% 55.7% 45.3% 27.1% 36.1% 38.8% 47.8% Race White ,672 18, , , % 24.9% 24.4% 21.1% 16.0% 15.1% 10.2% 12.5% 13.6% 20.4% Black , , % 23.8% 25.6% 21.3% 20.3% 18.9% 13.5% 13.9% 17.8% 21.5% Hispanic % 24.2% 29.0% 24.3% 17.3% 15.9% 14.4% 13.1% 15.6% 22.0% API % 21.2% 24.1% 20.0% 13.8% 15.1% 9.5% 11.0% 13.0% 19.4% Native American % 0.0% 26.3% 21.4% 11.0% 17.8% 11.1% 11.0% 16.2% 20.7% Other/unknown % 20.0% 28.3% 25.3% 17.9% 16.8% 13.3% 16.0% 21.2% 22.6% Abbreviations: AJCC, American Joint Committee on Cancer; API, Asian/Pacific Islander; NSCLC, nonsmall cell lung cancer; SCLC, small cell lung cancer. with no insurance (PR range, ; all P <.01), Medicaid (PR range, ; all P <.01), or Medicare (PR range, ; all P <.001) were significantly more likely to be untreated than patients with private insurance. There were statistically significant differences with regard to the percentage of untreated patients with stage IV cancer by median income and educational status (Table 3). For every 5% increase in the population without a high school education living in a patient s ZIP code, the percentage of untreated patients increased significantly (PR range, ; all P <.001 except uterus). Conversely, for every additional $10,000 of median income for the population living in a patient s ZIP code, the percentage of untreated patients decreased significantly (PR range, ; all P <.01 except uterus). DISCUSSION On the basis of the current analysis, representing 773,233 patients diagnosed with 8 common solid tumors in the United States over an 8-year period, nearly 1 in 5 patients presenting with stage IV solid tumors never receive anticancer therapy. In a hypothesis-generating analysis, we also observed that older age, racial and ethnic minority status, lack of medical insurance, and lower income were all associated with an increased likelihood of not receiving treatment. The percentage of untreated patients varied by primary tumor site from 11.1% to 25.5%. Not surprisingly, patients with breast and prostate cancer were the least likely to remain untreated, which may be related to the high rates of screening for these cancers 11 and the relatively tolerable hormonal therapies available for the treatment of metastatic disease. Patients with NSCLC had the highest rate of being untreated and accounted for > 50% of untreated patients during this time period. The percentage of untreated patients increased with age across all tumor subtypes. These findings are not unexpected because age-related comorbidities and decline in functional status have clear implications with regard to the risk-to-benefit ratio of systemic therapy. 12 A recent study Cancer December 1,
6 Table 3. Percentage of Patients With Untreated AJCC Stage IV Cancer by Tumor Site and Socioeconomic Factors (No. and Percentage Untreated) Factor Kidney Uterus NSCLC SCLC Rectum Colon Prostate Breast Cervix Total Insurance status None % 26.7% 26.8% 20.2% 20.2% 17.7% 14.4% 16.3% 18.9% 22.7% Private , , % 14.0% 16.6% 14.6% 9.2% 8.6% 7.2% 8.1% 9.2% 13.1% Medicaid % 25.6% 22.4% 16.3% 14.5% 14.7% 11.5% 10.4% 11.9% 18.2% Medicare ,745 13, , , % 30.8% 29.1% 25.2% 22.6% 20.2% 13.4% 17.5% 22.6% 25.2% Military % 0.0% 29.8% 21.7% 21.4% 20.8% 8.0% 12.8% 16.4% 24.0% Other/unknown % 22.2% 26.5% 25.9% 14.5% 17.7% 12.7% 14.2% 15.5% 21.8% Median rate of no high school education by ZIP code 31% , , % 26.6% 27.5% 22.1% 18.9% 18.4% 13.7% 15.2% 17.0% 23.0% 23%-30.9% , , % 25.8% 25.8% 22.0% 16.7% 16.4% 12.0% 12.6% 14.9% 21.6% 18%-22.9% , , % 24.9% 24.5% 20.1% 16.2% 15.6% 11.1% 12.6% 15.7% 20.4% 12%-17.9% , , % 23.0% 23.9% 21.2% 15.4% 15.3% 10.2% 12.5% 13.3% 20.0% <12% , , % 20.8% 22.9% 20.9% 15.8% 14.4% 9.7% 11.8% 11.8% 18.9% Unknown , % 31.3% 24.4% 22.0% 16.7% 14.4% 10.5% 12.7% 15.4% 20.2% Median income by ZIP code <$28, , , % 24.5% 27.5% 22.4% 19.6% 19.0% 13.4% 15.2% 17.9% 23.7% $28,000-$32, , , % 28.5% 25.8% 21.7% 16.5% 16.0% 11.3% 12.7% 14.9% 22.0% $33,000-$38, , , , % 21.1% 24.5% 20.9% 16.1% 15.7% 11.3% 12.3% 14.8% 20.3% $39,000-$48, , , % 24.7% 23.9% 20.8% 16.4% 15.5% 11.0% 12.5% 14.2% 20.2% >$49, , , % 23.1% 22.9% 21.1% 15.4% 14.8% 10.2% 12.5% 12.9% 18.7% Unknown % 31.3% 24.4% 21.9% 16.6% 14.4% 10.5% 12.7% 15.2% 20.2% Abbreviations: AJCC, American Joint Committee on Cancer; NSCLC, nonsmall cell lung cancer; SCLC, small cell lung cancer. by Wang et al 13 indicated that, in veterans aged > 65 years with NSCLC, advanced age was an even stronger predictor than comorbidity for receiving treatment. In this population, a high percentage of patients with metastatic disease did not receive treatment (66% of patients aged 65 years-74 years, 77% of patients aged 75 years-84 years, and 90% of patients aged > 85 years). 13 These results further highlight the potential disconnect between the efficacy of therapies in the setting of clinical trials and the effectiveness of such therapies when applied to the general population of patients with advanced cancer. There are likely multiple reasons why patients with metastatic cancer may not receive anticancer therapy, including appropriate reasons such as poor functional status, comorbidities, and patient preference. Furthermore, there are likely several factors that contribute to patients presenting with advanced, rather than early stage, cancer. Tumor biology, with rapid disease onset and progression, may play a predominant role in some patients. However, racial/ethnic minority status and/or poor access to care have previously been identified as factors associated with an increased likelihood of presenting with an advanced stage of disease at diagnosis For example, Halpern et al demonstrated that nonwhite patients who were without insurance or with Medicaid were at a significantly increased risk of presenting with advanced stage disease for breast, colorectal, bladder, prostate, uterine, thyroid, kidney, and lung cancers. 9 A propensity score analysis of patients treated at VA hospitals versus fee-for-service Medicare patients indicated that VA patients had 5952 Cancer December 1, 2012
7 Untreated Metastatic Cancer/Small et al Figure 4. Forest plots of prevalence ratios (PRs) of untreated patients with stage IV cancer are shown. Plots were based on (A) age (per 10-year increment), (B) percentage of patients without a high school education (per additional 5%), (C) income (per additional $10,000), (D) insurance type (vs private), and (E) race (vs white). Solid line indicates a PR of 1; dotted lines, reference; 95% CL, 95% confidence limit; LCL, lower confidence limit; UCL, upper confidence limit; NSCC, nonsmall cell cancer; SCC, small cell cancer; API, Asian/Pacific Islander. equivalent or better survival rates for colon cancer, NSCLC, SCLC, lymphoma, and multiple myeloma, suggesting potentially superior preventive care or cancer screening. 17 Other studies have observed decreased screening rates in racial minorities, underinsured patients, and the elderly. 18,19 Taken together, these findings suggest that certain patient groups may not only be more likely to present with cancers at later stages, but may also be less likely to receive any anticancer therapy whey they are ultimately diagnosed. It is interesting to note that the development of better tolerated and/or more effective treatments may have some impact on the number of patients who are untreated. For example, in the current study, the percentage of untreated patients with metastatic kidney cancer was 26.8% (CL, 23.4, 29.3) in the pre-vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) era ( ), and decreased to 22.8% (CL, 21.3, 24.0) in the VEGFR TKI era ( ).However,evenwiththeintroductionofbetter Cancer December 1,
8 therapies, there remains a large percentage of untreated patients. A strength of the current analysis is the large data set representing a diverse population of patients and the focus on a contemporary time period. In addition, because cancer registrars actively report no first-course treatment to the NCDB, the assignment of patients to the untreated category was not simply based on an absence of data regarding treatment. The trends observed, particularly with regard to the increased percentage of untreated patients with advancing patient age, add some further confidence to the validity of the data. However, the current study has several limitations. Foremost, we used the NCDB Public Benchmark Reports and did not have access to individual patient data. Therefore, we could not perform multivariable analysis to determine which potentially related variables associated with an increased prevalence of untreated metastatic cancer retained independent significance. Therefore, the findings regarding patient characteristics associated with an increased likelihood of being untreated can only be considered hypothesis-generating. Further evaluation using individual patient data are warranted. Although the NCDB includes data for >75% of new cancer cases in the United States annually, CoCapproved hospitals often provide more cancer-related services (including cancer screening, chemotherapy, and radiotherapy) than non-coc-accredited hospitals and therefore these findings may not be generalizable to non- CoC-accredited hospitals and may, in fact, be an underestimation of the prevalence of this group. Finally, the current study focused on patients with advanced/metastatic disease at the time of the initial cancer diagnosis and the percentage of untreated patients with metastatic disease may be substantially lower for patients initially presenting with earlier stage disease and later developing metastatic recurrence. In summary, a large percentage of patients presenting with advanced solid tumors at the time of their initial cancer diagnosis receive no anticancer therapy. Further studies are necessary to better define the reasons for this lack of treatment, particularly because these relate to access to care, health literacy, and treatment disparities. FUNDING SUPPORT Funding received from the Doris Duke Charitable Foundation. CONFLICT OF INTEREST DISCLOSURES Dr. Wisnivesky is a member of the research board of EHE International. He has received lecture fees from Novartis Pharmaceuticals, acted as a consultant for United BioSource Corporation, and received a chronic obstructive pulmonary disease grant from GlaxoSmithKline. REFERENCES 1. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV nonsmall cell lung cancer. Chest. 2003;123 (suppl 1):226S-243S. 2. O Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(suppl 3): Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One. 2010;5:e Li X, Butts C, Fenton D, King K, Scarfe A, Winget M. Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer. Ann Oncol. 2011;22: Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000;117: Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. NEnglJMed. 2002;346: Sonpavde G, Watson D, Tourtellott M, et al. Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community. Clin Oncol. 30, 2012 (suppl 5; abstr 285). 8. Winchester DP, Stewart AK, Phillips JL, Ward EE. The national cancer data base: past, present, and future. Ann Surg Oncol. 2010;17: Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9: Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2012;62: Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening [published online ahead of print January 19, 2012]. CA Cancer J Clin. doi: / caac Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29: Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on nonsmall-cell lung cancer treatment in older veterans [published online ahead of print March 26, 2012]. J Clin Oncol. 14. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287: Bradley CJ, Given CW, Roberts C. Disparities in cancer diagnosis and survival. Cancer. 2001;91: SchwartzKL,Crossley-MayH,VigneauFD,BrownK,Banerjee M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control. 2003;14: Landrum MB, Keating NL, Lamont EB, et al. Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol. 2012;30: Chen JY, Diamant A, Pourat N, Kagawa-Singer M. Racial/ethnic disparities in the use of preventive services among the elderly. Am J Prev Med. 2005;29: Hoffman-Goetz L, Breen NL, Meissner H. The impact of social class on the use of cancer screening within three racial/ethnic groups in the United States. Ethn Dis. 1998;8: Cancer December 1, 2012
Financial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationFinancial Disclosure. Team. Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer
Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer Melanie Goldfarb MD, MSc, FACS, FACE John Wayne Cancer Institute at PSJHC, Santa Monica,
More informationTools, Reports, and Resources
Tools, Reports, and Resources What the National Cancer Database (NCDB) does for CoC-Accredited Programs By using the NCDB, CoC-accredited programs can proactively improve delivery and quality of care for
More information6/20/2012. Co-authors. Background. Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy. Age 70 Years
Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy - among Locoregional Breast Cancer Patients Under Age 70 Years Xiao-Cheng Wu, MD, MPH 2012 NAACCR Annual Conference June
More informationAnnual Report to the Nation on the Status of Cancer, , Featuring Survival Questions and Answers
EMBARGOED FOR RELEASE CONTACT: Friday, March 31, 2017 NCI Media Relations Branch: (301) 496-6641 or 10:00 am EDT ncipressofficers@mail.nih.gov NAACCR: (217) 698-0800 or bkohler@naaccr.org ACS Press Office:
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationImpact of Poor Healthcare Services
Competency 3 Impact of Poor Healthcare Services Updated June 2014 Presented by: Lewis Foxhall, MD VP for Health Policy Professor, Clinical Cancer Prevention UT MD Anderson Cancer Center Competency 3 Objectives
More informationPerks and Quirks: Using the NCDB Participant User File (PUF) for Outcomes Research
Perks and Quirks: Using the NCDB Participant User File (PUF) for Outcomes Research Daniel J. Boffa, MD Thoracic Surgery Yale University School of Medicine None Disclosures Why Me? No formal affiliation
More informationPredictors of Palliative Therapy Receipt in Stage IV Colorectal Cancer
Predictors of Palliative Therapy Receipt in Stage IV Colorectal Cancer Osayande Osagiede, MBBS, MPH 1,2, Aaron C. Spaulding, PhD 2, Ryan D. Frank, MS 3, Amit Merchea, MD 1, Dorin Colibaseanu, MD 1 ACS
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationAn Overview of Disparities Research in Access to Radiation Oncology Care
An Overview of Disparities Research in Access to Radiation Oncology Care Shearwood McClelland III, M.D. Department of Radiation Medicine Oregon Health & Science University Portland, Oregon Disclosures
More informationEpidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
More informationCancer Care in the Veterans Health Administration
Cancer Care in the Veterans Health Administration Michael J Kelley, MD National Program Director for Oncology Department of Veterans Affairs Professor of Medicine Duke University Medical Center Chief,
More informationAlthough surgical resection has been the traditional standard-of-care
Original Article Disparities in Treatment of Patients with Inoperable Stage I Non Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD,* Renuka Malik, MD, Mike Spiotto, MD, PhD,* Usama
More information!"#$ Oncology Outcomes Report
!"#$ Oncology Outcomes Report The Cleveland Clinic Florida Cancer Institute is dedicated to the comprehensive care of patients with cancer. Oncologists collaborate with a variety of physicians across multiple
More informationOtis Brawley, MD Chief Medical & Scientific Officer American Cancer Society
Otis Brawley, MD Chief Medical & Scientific Officer American Cancer Society Otis W. Brawley, MD, MACP, FASCO, FACE Chief Medical and Scientific Officer American Cancer Society Professor of Hematology,
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationDisparities in Progress against Cancer in the USA
Disparities in Progress against Cancer in the USA Ahmedin Jemal, DVM, PhD American Cancer Society ASPO Webinar November 29, 2018 Progress in reducing cancer death rates in the US, 1970-2015 240 220 215
More informationORIGINAL ARTICLE. US Mortality Rates for Oral Cavity and Pharyngeal Cancer by Educational Attainment
ORIGINAL ARTICLE US Mortality Rates for Oral Cavity and Pharyngeal Cancer by Educational Attainment Amy Y. Chen, MD, MPH; Carol DeSantis, MPH; Ahmedin Jemal, PhD Objective: To describe trends in mortality
More informationSurvival among Native American Adolescent and Young Adult Cancer Patients in California
Survival among Native American Adolescent and Young Adult Cancer Patients in California Cyllene R. Morris, 1 Yi W. Chen, 1 Arti Parikh-Patel, 1 Kenneth W. Kizer, 1 Theresa H. Keegan 2 1 California Cancer
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationPopulations of Color in Minnesota
Populations of Color in Minnesota Health Status Report Update Summary Fall 2002 Center for Health Statistics Minnesota Department of Health Table of Contents Part I: Birth Related Indicators...1 Low Birthweight...1
More informationVariation in Insurance Status by Patient Demographics and Tumor Site Among Nonelderly Adult Patients With Cancer
Variation in Insurance Status by Patient Demographics and Tumor Site Among Nonelderly Adult Patients With Cancer Stephen R. Grant, BS 1 ; Gary V. Walker, MD, MPH, MS 1 ; B. Ashleigh Guadagnolo, MD, MPH
More informationEvaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials
Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials Mary Beth Terry, PhD Department of Epidemiology Mailman School of Public Health Racial and Ethnic Disparities in
More informationTHE USE, EFFECTIVENESS, AND SAFETY OF BEVACIZUMAB IN OLDER ADULTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER. Aaron Jacob Katz.
THE USE, EFFECTIVENESS, AND SAFETY OF BEVACIZUMAB IN OLDER ADULTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER Aaron Jacob Katz A dissertation submitted to the faculty of the University of North Carolina
More informationRacial and Socioeconomic Disparities in Appendicitis
Racial and Socioeconomic Disparities in Appendicitis Steven L. Lee, MD Chief of Pediatric Surgery, Harbor-UCLA Associate Clinical Professor of Surgery and Pediatrics David Geffen School of Medicine at
More informationCancer Facts & Figures for African Americans
Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases
More informationDefinition of Health/Healthcare disparities. Health/Healthcare. Healthcare Disparities
Healthcare Disparities Darrell M. Gray, II, MD, MPH Assistant Professor Deputy Director, Center for Cancer Health Equity OSU Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
More informationFinancial Disclosure. Learning Objectives. Use of Genomics in the NCDB, Early Data Analysis. I have no financial disclosures
Use of Genomics in the NCDB, Early Data Analysis Katharine Yao, MD Chief, Division of Surgical Oncology NorthShore University HealthSystem Chair, QI Committee, NAPBC Financial Disclosure I have no financial
More informationTheresa Keegan, Ph.D., M.S. Associate Professor Department of Internal Medicine Division of Hematology and Oncology
Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: A population- based study Theresa Keegan, Ph.D., M.S. Associate Professor Department
More informationCancer in Rural Illinois, Incidence, Mortality, Staging, and Access to Care. April 2014
Cancer in Rural Illinois, 1990-2010 Incidence, Mortality, Staging, and Access to Care April 2014 Prepared by Whitney E. Zahnd, MS Research Development Coordinator Center for Clinical Research Southern
More informationINTRODUCTION MATERIALS AND METHODS
ORIGINAL ARTICLE Demographic and socioeconomic factors predictive of compliance with American Thyroid Association guidelines for the treatment for advanced papillary thyroid carcinoma Ashley E. Wenaas,
More informationDisparities in Cancer Treatment Among Patients Infected With the Human Immunodeficiency Virus
Disparities in Cancer Among Patients Infected With the Human Immunodeficiency Virus Gita Suneja, MD, MSHP 1 ; Chun Chieh Lin, PhD 2 ; Edgar P. Simard, PhD 3 ; Xuesong Han, PhD 2 ; Eric A. Engels, MD 4
More informationFinancial Disclosure. Learning Objectives. Evaluation of Chemotherapy in Last 2 Weeks of Life: CAMC Patterns of Care
Evaluation of Chemotherapy in Last 2 Weeks of Life: CAMC Patterns of Care Steven J. Jubelirer, MD Clinical Professor Medicine WVU Charleston Division Senior Research Scientist CAMC Research Institute Charleston
More informationBurden of Cancer in California
Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality
More informationIncidence and Determinants of 1-Month Mortality after Cancer-Directed Surgery
Annals of Oncology Advance Access published November 27, 2014 1 Incidence and Determinants of 1-Month Mortality after Cancer-Directed Surgery B.A. Mahal 1,*, G. Inverso 2,*, A.A. Aizer 3, D.R. Ziehr 1,
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2005 December 15; 104(12 Suppl): 2989 2998. 1999 2001 Cancer Mortality Rates for Asian and Pacific Islander Ethnic Groups
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationUsing claims data to investigate RT use at the end of life. B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center
Using claims data to investigate RT use at the end of life B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center Background 25% of Medicare budget spent on the last year of life.
More informationWhat is the Impact of Cancer on African Americans in Indiana? Average number of cases per year. Rate per 100,000. Rate per 100,000 people*
What is the Impact of Cancer on African Americans in Indiana? Table 13. Burden of Cancer among African Americans Indiana, 2008 2012 Average number of cases per year Rate per 100,000 people* Number of cases
More informationCancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)
O COLON MEASURE SPECIFICATIONS Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff
More informationRacial variation in receipt of quality radiation therapy for prostate cancer
https://doi.org/10.1007/s10552-018-1065-5 BRIEF REPORT Racial variation in receipt of quality for prostate cancer Daniel J. Lee 1 Zhiguo Zhao 2 Li Ching Huang 2 Tatsuki Koyoma 2 Matthew J. Resnick 1 David
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 21 Annual Report Quality Study Adherence to Adjuvant Systemic Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Grapevine
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationTrends in Cancer CONS Disparities between. W African Americans and Whites in Wisconsin. Carbone Cancer Center. July 2014
Photo Illustration by Lois Bergerson/UW SMPH Media Solutions Trends in Cancer CONS IN IS Disparities between W s and s in Wisconsin July 214 Carbone Cancer Center Dane County Cancer Profile 214 UNIVERSITY
More informationThe American Cancer Society estimates that there will be
ORIGINAL ARTICLE Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,* David M. Kent, MD, MS, and Gary M.
More informationAccess and Outcomes Among Minority Transplant Patients, , with a Focus on Determinants of Kidney Graft Survival
American Journal of Transplantation 2010; 10 (Part 2): 1090 1107 Wiley Periodicals Inc. Special Feature No claim to original US government works Journal compilation C 2010 The American Society of Transplantation
More informationQuestionnaire. 1) Do you see men over the age of 40? 1. Yes 2. No
Questionnaire 1) Do you see men over the age of 40? 1. Yes 2. No 2) In what state do you practice? (drop-down menu of 50 states and District of Columbia) 3) What is your medical specialty? (Please select
More informationRacial Variation In Quality Of Care Among Medicare+Choice Enrollees
Racial Variation In Quality Of Care Among Medicare+Choice Enrollees Black/white patterns of racial disparities in health care do not necessarily apply to Asians, Hispanics, and Native Americans. by Beth
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationRacial and Ethnic Differences in Hospice Enrollment Among Children With Cancer
Pediatr Blood Cancer 2013;60:1662 1666 Racial and Ethnic Differences in Hospice Enrollment Among Children With Cancer Rachel Thienprayoon, MD, 1,2 * Simon Craddock Lee, PhD, MPH, 3,4 David Leonard, PhD,
More informationAdjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study
COLON CANCER ORIGINAL RESEARCH Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study Rosemary D. Cress 1, Susan A. Sabatino 2, Xiao-Cheng Wu 3,
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 216 Annual Report Quality Study Adherence to Adjuvant System Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Irving
More informationRacial Disparities In The Treatment Of Non-Surgical Patients With Lung Cancer. S Annangi, M G Foreman, H P Ravipati, S Nutakki, E Flenaugh
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 18 Number 1 Racial Disparities In The Treatment Of Non-Surgical Patients With Lung Cancer S Annangi, M G Foreman, H P Ravipati, S Nutakki, E
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 1 Annual Report Quality Study Adherence to Adjuvant Systemic Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center McKinney
More informationPatient and Hospital Characteristics Associated with Nephron-Sparing Surgery for Small, Localized Kidney Cancers in California,
Patient and Hospital Characteristics Associated with Nephron-Sparing Surgery for Small, Localized Kidney Cancers in California, 2012-2015 Brenda M. Giddings, M.A. California Cancer Reporting and Epidemiologic
More informationWHAT FACTORS INFLUENCE AN ANALYSIS OF HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011
WHAT FACTORS INFLUENCE HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AN ANALYSIS OF AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011 WHAT IS AGGRESSIVE EOL CARE? Use of ineffective medical
More informationCancer in New Mexico 2017
Cancer in New Mexico 0 Please contact us! Phone: 0-- E-Mail: nmtr-info@salud.unm.edu URL: nmtrweb.unm.edu TABLE OF CONTENTS Introduction... New Cases of Cancer Estimated Number of New Cancer Cases Description
More informationTreatment disparities for patients diagnosed with metastatic bladder cancer in California
Treatment disparities for patients diagnosed with metastatic bladder cancer in California Rosemary D. Cress, Dr. PH, Amy Klapheke, MPH Public Health Institute Cancer Registry of Greater California Introduction
More information2015 Patient Outcomes Report
2015 Patient Outcomes Report Message from the Breast Leadership Team and Cancer Committee: On behalf of the Breast Leadership Team and Cancer Committee of The Hospitals, we are pleased to present to you
More informationThe Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer
J. Racial and Ethnic Health Disparities (5) :4 DOI.7/s465-4-55-x The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer Casey DeDeugd & Makito Miyake & Diego Aguilar
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More information2018 Texas Cancer Registry Annual Report
2018 Texas Cancer Registry Annual Report As Required by Texas Health and Safety Code Section 82.007 November 2018 Table of Contents Executive Summary... 1 1. Introduction... 2 2. Background... 3 Cancer
More informationCancer in New Mexico 2014
Cancer in New Mexico 2014 Please contact us! Phone: 505-272-5541 E-Mail: info@nmtr.unm.edu http://som.unm.edu/nmtr/ TABLE OF CONTENTS Introduction... 1 New Cases of Cancer: Estimated Number of New Cancer
More informationIdentifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas
Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas Mary T. Austin, MD, MPH Assistant Professor, Pediatric Surgery University of Texas Health Science
More informationAdvancing Health Equity in Lung Cancer Outcomes
Advancing Health Equity in Lung Cancer Outcomes Edwin J Jackson Jr. DO Pulmonary and Critical Care Medicine Disclosures Funding: American Thoracic Society 2 1 Lecture Outline Cancer Disparities Smoking
More informationNational Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)
National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health
More informationAmerican Cancer Society Progress Report. December 2016
American Cancer Society Progress Report December 2016 2015 Goals Incidence: By 2015, 25% reduction (unlikely to meet goal) Baseline 1992-2013: 12.1% reduction Latest joinpoint trend: -1.5% APC (2009-2013)
More informationCANCER FACTS & FIGURES For African Americans
CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5
More informationDr. Thomas D Amico serves as a consultant for Scanlan. The other authors have no conflicts of interest to report.
Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung Cancer Brian C Gulack, MD; Jeffrey Chi-Fu Yang, MD;
More informationThe role of second-line chemotherapy for advanced nonsmall
ORIGINAL ARTICLE Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States Real-World Considerations for Maintenance Therapy David E. Gerber, MD,* Drew
More informationINITIAL SYSTEMIC TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER
INITIAL SYSTEMIC TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER Fran Maguire, MPH, PhD candidate California Cancer Reporting and Epidemiologic Surveillance (CalCARES) Program NAACCR Annual Conference
More informationGastrointestinal Cancer
Gastrointestinal Cancer Referral to Medical Oncology: A Crucial Step in the Treatment of Older Patients with Stage III Colon Cancer RuiLi Luo, a,b Sharon H. Giordano, d Jean L. Freeman, a c Dong Zhang,
More informationA review of Socio Economic Factors impact on Cancer incidence
A review of Socio Economic Factors impact on Cancer incidence Abstract K.B.R.Senavirathne 1 Cancer is a leading cause of death worldwide. Cancer is the uncontrolled growth of cells, which can invade and
More information2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationEvolution of CoC within ACoS. American College of Surgeons Commission on Cancer Current Activities and Future Initiatives November 5,2005
American College of Surgeons Commission on Cancer Current Activities and Future Initiatives November 5,25 FREDERICK L. GREENE, MD Chair, Commission on Cancer Evolution of CoC within ACoS Two plans proposed
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationJohn T. Mather Memorial Hospital and St. Charles Hospital Community Health Needs Assessment: Cancer Executive Summary
John T. Mather Memorial Hospital and St. Charles Hospital 2015 Community Health Needs Assessment: Cancer Executive Summary Purpose The purpose of the Mather-St. Charles Cancer Program 2015 Community Health
More informationPRINCIPLES FOR ELIMINATING DISPARITIES THROUGH HEALTH CARE REFORM. John Z. Ayanian, MD, MPP
PRINCIPLES FOR ELIMINATING DISPARITIES THROUGH HEALTH CARE REFORM John Z. Ayanian, MD, MPP Harvard Medical School Brigham and Women s Hospital Harvard School of Public Health 8 th Annual National Summit
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationA New Measure to Assess the Completeness of Case Ascertainment
A New Measure to Assess the Completeness of Case Ascertainment Barnali Das, Ph.D. Linda Pickle, Ph.D. Eric J. (Rocky) Feuer, Ph.D. Lin Clegg, Ph.D. Surveillance Research Program, National Cancer Institute
More informationCancer prevalence. Chapter 7
Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.
More informationBreast Reconstruction After Mastectomy Among Department of Defense Beneficiaries by Race
Breast Reconstruction After Mastectomy Among Department of Defense Beneficiaries by Race Lindsey R. Enewold, PhD, MPH 1 ; Katherine A. McGlynn, PhD, MPH 2 ; Shelia H. Zahm, ScD 2 ; Jill Poudrier, MS 3
More informationC ancer represents a serious threat to the
674 ETHICS Access and equity to cancer care in the USA: a review and assessment L A Siminoff, L Ross... Cancer represents a serious threat to the health of women and men living in the USA. As the second
More informationTruman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
More informationCancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition
Cancer Disparities in Arkansas: An Uneven Distribution Prepared by: Martha M. Phillips, PhD, MPH, MBA For the Arkansas Cancer Coalition Table of Contents Page Burden of Cancer 3 Cancer Disparities 3 Cost
More informationPartnering for Hope 2015 ANNUAL REPORT
Partnering for Hope 2015 ANNUAL REPORT PATIENT CARE EVALUATION STUDY DISPARITIES IN THE MANAGEMENT OF ELDERLY BREAST CANCER PATIENTS Cynthia Osborne, MD, Mabel Mardones, MD, Janet Reynolds, CTR, Andrew
More informationAlarge body of evidence documents
Is Spending More Always Wasteful? The Appropriateness Of Care And Outcomes Among Colorectal Cancer Patients An across-the-board reduction in services might eliminate valuable care in addition to reducing
More informationSurvival Inequalities among Children, Adolescents and Young Adults with Acute Leukemia in California Renata Abrahão, MD MSc PhD
Survival Inequalities among Children, Adolescents and Young Adults with Acute Leukemia in California Renata Abrahão, MD MSc PhD California Cancer Registrars Association Sacramento November 3 rd, 2016 Objectives
More informationRacial inequalities in health care and health outcomes between
AMatterOfRace:Early-Versus Late-Stage Cancer Diagnosis African Americans receive their cancer diagnoses at more advanced stages of the disease than whites do. by Beth A. Virnig, Nancy N. Baxter, Elizabeth
More informationLANDMARK MEDICAL CENTER CANCER PROGRAM YEAR IN REVIEW 2013
LANDMARK MEDICAL CENTER CANCER PROGRAM YEAR IN REVIEW 2013 Landmark Medical Center offers a comprehensive cancer care services to our patients. LMC Cancer program is committed to ensure that patients receive
More informationCancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006
Chinese Journal of Cancer Original Article Cancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006 Xiao-Pan Li 1, Guang-Wen Cao 2, Qiao
More informationClinicopathological and Survival Pattern in Lung Cancer Patients of Different Age Group
International Journal of Clinical Oncology and Cancer Research 2018; 3(3): 25-29 http://www.sciencepublishinggroup.com/j/ijcocr doi: 10.11648/j.ijcocr.20180303.12 Clinicopathological and Survival Pattern
More informationOverview of Gynecologic Cancers in New Jersey
Overview of Gynecologic Cancers in New Jersey New Jersey State Cancer Registry Antoinette M. Stroup, PhD presented at: Gynecologic Cancer Symposium: Striving for a Healthier Tomorrow, Today November 19,
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationCancer in the Northern Territory :
Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have
More informationLeveraging Your Cancer Registry: A Strategy for Survey Success
CoC-trained consultants on staff Leveraging Your Cancer Registry: A Strategy for Survey Success Toni Hare, RHIT, CTR CoC-trained Consultant Vice President, CHAMPS Oncology November 27, 2012 Georgia s Best
More information